pTau217 and Aβ42 are FDA-approved biomarkers for Alzheimer's detection in symptomatic patients and can predict future dementia risk in healthy individuals.

“Higher pTau217 levels = faster cognitive decline.”

“pTau217 and A𝛃42 are recent FDA-approved biomarkers for Alzheimer's detection in symptomatic patients.”

“A @NatureAging study found pTau217 levels in healthy people predicted future cognitive decline as accurately as brain scans.”

“Serum pTAU217 is a marker for Alzheimer's disease.”

“Cognitively unimpaired individuals with pTau217 levels in the highest 25% showed a 57% elevated risk of future cognitive decline.”

“The research proposes that p-TAU217 can serve as an initial screening tool in healthy individuals.”

“Elevated concentrations of p-TAU217 can also be detected in the blood, higher concentrations predict faster disease progression.”

“Cognitively unimpaired individuals in the highest 25% of pTau217 levels demonstrated a 57% elevated risk of future cognitive decline.”